Phase 2b Study to Test Safety and Effectiveness of PF-08653945 and PF-08653944 Alone or Together for Weight Loss in Adults with Overweight or Obesity

What this Trial Is About

Researchers are studying the safety and effects of two drugs, PF-08653945 and PF-08653944, given alone or together for weight loss in adults with overweight or obesity. This Phase 2b trial compares these drugs to a placebo to better understand their impact on body weight over time. The study is designed to evaluate different doses and combinations of these drugs to find the most effective approach. Participants receive subcutaneous injections of either PF-08653945 alone, PF-08653945 combined with PF-08653944, PF-08653944 alone, or a placebo. The study uses a randomized, double-blind design with multiple cohorts receiving different drug combinations or placebo. Treatments are administered as injections under the skin over a planned period of 48 weeks, with follow-up extending to 70 weeks to monitor safety and outcomes. During the study, participants will have their body weight measured at baseline and regularly through Week 48 and Week 60 to track changes. Researchers will assess the percentage of weight loss and monitor any treatment-emergent or serious adverse events up to Week 70. Participants will attend scheduled visits for injections and evaluations throughout the trial, which lasts for over a year in total.

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)